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Abstract 
Background 
Low adherence to oral bisphosphonates is a common problem that jeopardizes 
the efficacy of treatment of osteoporosis. No clear screening strategy for the 
assessment of compliance is widely accepted in these patients.  
Methods 
The International Osteoporosis Foundation and the European Calcified Tissue 
Society have convened a working group to propose a screening strategy to detect 
a lack of adherence to these drugs. The question to answer was whether  the 
bone turnover markers (BTMs) PINP and CTX can be used to identify low 
adherence in patients with postmenopausal osteoporosis initiating oral 
bisphosphonates for osteoporosis. The findings of the TRIO study specifically 
address this question and were used as the basis for testing the hypothesis. 
Results 
Based on the findings of the TRIO study, specifically addressing this question, the 
working group recommends measuring PINP and CTX at baseline and three 
months after starting therapy to check for a decrease above the least significant 
change (decrease of more than 38% for PINP and 56% for CTX). Detection rate 
for the measurement of PINP is 84%, for CTX 87% and, if variation in at least one 
is considered when measuring both, the level of detection is 94.5%.  
Conclusions 
If a significant decrease is observed the treatment can continue but if no 
decrease occurs the clinician should reassess to identify problems with the 
treatment, mainly low adherence 
 
 
Keywords: Adherence, Bisphosphonates, Osteoporosis treatment, Screening, 
Position paper 
 
Mini Abstract: 
Adherence to oral bisphosphonates is low. A screening strategy is proposed 
based on the response of biochemical markers of bone turnover after three 
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months of therapy. If no change is observed, the clinician should reassess the 
adherence to the treatment and also other potential issues with the drug.   
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Introduction 
 
Oral bisphosphonates are a first line treatment for osteoporosis. However, 
as in any other chronic diseases, low adherence is a common clinical problem. It 
has been observed that the adherence to oral bisphosphonates is as low as 59 (1) 
or 43% (2) at one year and appears to be worse with generic medications (3). 
This problem significantly jeopardizes the anti-fracture efficacy and cost 
effectiveness (4). Few interventions to improve adherence have been tested, and 
the ones that may be effective include education programs (5, 6).  
Monitoring adherence is the first step in managing this problem since it 
detects those patients with problems with the medication. The response of bone 
turnover markers to therapy, in the individual patient, is one of the methods 
suggested for treatment monitoring (7). Their advantage is that they are widely 
available, affordable and clinicians are familiar with their interpretation. They 
reflect the early effect of the drug on bone tissue (8). Low response may be 
detected shortly after treatment has been started and may indicate low 
adherence, low bioavailability, interactions with other drugs or the presence of 
secondary osteoporosis (9). Moreover, bone turnover marker response has been 
used as an intervention for improving treatment adherence(5) (10). 
 Serum PINP (Procollagen type I N- terminal propeptide) and CTX 
(Collagen type I C-terminal telopeptide)  have been recommended as reference 
markers by a committee of the International Osteoporosis Foundation (IOF) and 
the International Federation of Clinical Chemistry and Laboratory Medicine 
(IFCC) (8). Oral bisphosphonates decrease levels of PINP and CTX rapidly in most 
patients, beyond the least significant change (LSC), the margin of change as 
demonstrated from the results of a recent controlled trial (11). Therefore they 
are an excellent candidate for screening treatment effect early after starting the 
drug and may detect any problem with adherence.  
The aim of the present work is to establish a clinically feasible and 
practical strategy, based on bone turnover marker measurement, to detect a lack 
of response which may indicate a problem with adherence to oral osteoporosis 
drugs, specifically amino bisphosphonates, and give a recommendation for their 
use in clinical practice in the individual patient. For this the International 
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Osteoporosis Foundation and the European Calcified Tissue Society have 
convened a working group to answer this question. 
 
 
Methods 
 
The Working Group (WG) proposed the following question: Can the bone 
turnover markers (BTMs) PINP and CTX be used to identify low adherence in 
patients with postmenopausal osteoporosis initiating oral bisphosphonates for 
osteoporosis?  
 
Bone turnover markers: 
 
Measurement of bone turnover markers is considered as the most specific 
early method for measuring the biological effect of bisphosphonates. The WG 
focused on the two markers prioritized by the IOF, namely serum CTX and PINP. 
It is necessary to know what proportion of patients with osteoporosis has 
changes in these markers that exceed the least significant change when taking 
oral bisphosphonate therapy.  This proportion provides the detection rate of the 
test (i.e., the sensitivity). The least significant change is defined here as the 95% 
confidence bounds for change in patients treated with bisphosphonates for 12 
weeks; thus, only 2.5% of untreated patients would exceed the least significant 
change (the false positive rate). Responders are considered as those patients 
who show changes in BTMs that exceed the LSC. The levels established for LSC 
were 56% decrease for CTX and 38% decrease for PINP (11). Two 
measurements of bone turnover markers, at baseline and three months after the 
prescription, are recommended. This 3 month interval is long enough to be  able 
to detect the change, is acceptable to the patient and represents the period 
during which treatment is often discontinued (12). Where baseline levels were 
not available, ‘response’ was also considered if the BTM were below the 
premenopausal mean (32 ng/L for CTX and 28 ug/L for PINP).  
 
Analysis of the TRIO Study 
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The primary source of information to establish the reference values for 
response rate is the TRIO study (11, 13). The TRIO study was so named as it was 
a study of three drugs (a trio of drugs). Under conditions of a controlled clinical 
trial, the results of the TRIO study can be assumed to be a benchmark for 
response of turnover markers. 
The TRIO study was a single-center randomized controlled trial of three 
oral bisphosphonates (alendronate, ibandronate and risedronate) at their 
licensed doses to study their effect on bone turnover markers and bone mineral 
density in postmenopausal osteoporosis.  The study specifically addresses the 
proportion of patients initiating oral bisphosphonates that show decreases in 
BTMs beyond the LSC after three months of therapy. The least significant change 
used was 2-tailed, p<0.05, thus we can be 95% sure that a change (up or down) 
as large as this, or larger, is significant. Furthermore, to minimize variability 
standardized sample collection, appropriate instructions to the patient and 
exclusion of individuals with fracture in the preceding 12 months were applied. 
We have focused on 3 months for simplicity, but the window could be widened, 
especially for PINP, and in an unpublished analysis we found that a later 
measurement did not affect the results. 
The TRIO study included 172 women with postmenopausal osteoporosis 
ages 53-84 who were treated for up to 2 years. There was a concurrent (non-
randomized) control group of 87 premenopausal women ages 35 to 40 years. 
Women with osteoporosis were entered into an open label, parallel, randomized 
intervention with the three commonly-used oral bisphosphonates, alendronate, 
ibandronate and risedronate (11) along with calcium and vitamin D 
supplementation. 
Blood was taken in the fasting state between 0800 and 1000 before any 
supplement was given (-1 week), one week on supplement (0 week) and after 
starting bisphosphonates (1, 2, 4, 12, 13, 48 and 96 weeks). This analysis will use 
the -1 week as baseline and the average of the 12 and 13-week samples for on 
treatment. Biochemical measurements included serum CTX and PINP using the 
IDS iSYS automated immunoassay platform. All specimens were collected fasting, 
frozen at -80ªC and were measured in one analytical batch. Many other 
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measurements were made of biochemical variables as well as bone density, but 
these are not included here.  
Adherence was evaluated by the Medication Event Monitoring System (MEMS) 
caps. Good adherence was defined as taking more than 80% of tablets over 48 
weeks. 
 
Detection rate 
 
An additional analysis on the TRIO results was performed to identify the 
proportion of patients receiving oral bisphosphonates that show decreases in 
each of the two proposed markers, CTX and PINP, as well as the proportion of 
cases that showed this change with either one of the other. From this, we 
calculated the detection rate for a single marker and for both markers, 
considering decrease in at least one of the markers beyond the LSC as a positive 
test.  
 
The formula for calculating detection rate was: 
                                                  A (positives) 
Detection rate =  
                                      A (positives)+ C (negatives)  
 
‘positives’ describe  the cases showing a decrease > LSC in one or both markers; 
‘negatives’ describe  the cases with no change or a change less than the LSC. 
 
 
 
Results 
 
The characteristics of the TRIO population are described in detail in the 
original publication [13].  In Table 1 are summarized the baseline values for each 
of the treatment groups, the values after three months of treatment and the 
percentage of decrease in CTX and PINP each for each drug (see also Figure 1).  
Good adherence, defined as taking more than 80% of tablets over 48 
weeks, was found in 104/135 subjects who completed 48 weeks. This was 
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associated with a 79% decrease in CTX as compared to low adherence, which 
was associated with a 64% decrease. Also it was associated with a 67% decrease 
in PINP as compared to low adherence, which was associated with a 51% 
decrease.  However, it has to be pointed out that the relationship between 
adherence and response to BPs is not a simple linear one and very low 
adherence is necessary to have no response (Table 2).  
Responders were considered as those cases with a decrease in markers 
more than the LSC, based on a decrease in CTX of 56% and a decrease in PINP of 
38%. The lumbar spine BMD (bone mineral density) increase at 96 weeks in CTX 
responders was 6.0% and 1.3% in non-responders. The total hip BMD increase at 
96 weeks in CTX responders was 3.2% and 1.0% in non-responders. The lumbar 
spine BMD increase at 96 weeks in PINP responders was 6.2 and 2.3% in non-
responders. The total hip BMD increase at 96 weeks in PINP responders was not 
different to non-responders. All these changes were independent on baseline 
values of turnover markers. Responders were considered those cases with a 
decrease in markers more than the LSC.  
The average decrease for CTX ranged from 68 to 81% and for PINP 
between 48 and 63% for the different treatment arms. For the different 
bisphosphonates, the percentage of individuals with a decrease beyond the LSC 
ranged from 78 to 98% for CTX and between 75 and 94% for PINP (Table 1).  
Table 3 summarizes the detection rate for the overall cohort, that is, the 
percentage of individuals in the overall cohort that show a decrease in CTX, PINP, 
beyond the LSC, or at least in one of them if both are measured, after three 
months of initiating therapy. For CTX the detection rate reaches a 87%, for PINP 
84% and, if decrease in at least one is considered when measuring both, the level 
of detection is 94.5% (Table 3). This means that the patients are taking and 
responding to the medication. Based on these results, a screening strategy is 
proposed as summarized in Figure 2. In brief, after measuring bone turnover 
markers before initiating medication, a second measurement is performed at 
three months. If the decrease does not exceed the LSC the clinician should 
reassess the treatment, mainly the adherence and, eventually, if an underlying 
cause of secondary osteoporosis or low response to the drug has not been 
previously detected.  
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A ‘response’ was also considered if the BTM were below the 
premenopausal mean (which was 32 ng/L for CTX and 28 ug/L for PINP). The 
baseline CTX and PINP were above these thresholds in 91 and 89% of women, 
respectively. The CTX values after 12 weeks of treatment were below these 
thresholds in 86%, 96% and 83% for ibandronate, alendronate and risedronate, 
respectively. . The PINP values after 12 weeks of treatment were below these 
thresholds in 96%, 82% and 75% for ibandronate, alendronate and risedronate, 
respectively. This approach is useful if there is no baseline BTM available. 
In practice, we wouldn’t usually repeat the measurement of CTX and PINP 
at both 12 and 13 weeks on treatment. In an unpublished analysis, we checked 
whether the responder rates were the same with just the 12-week measurement 
and whether we defined response by the least significant change or by being 
below the premenopausal mean, the number responding was only 1 to 3% fewer. 
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Discussion 
 
The working group recommends a screening policy for assessing 
adherence to oral bisphosphonates given as treatment for osteoporosis, by 
measuring PINP and CTX three months after starting therapy. At this time-point 
we would only expect 2.5% of untreated patients to exceed the least significant 
changes of 56% for CTX and 38% for PINP, yet with the oral bisphosphonate 
therapy overall, we found that 75-98% of women responded. 
This strategy fulfills the requirements for a screening procedure. A 
screening test needs to offer a high detection rate and perform well when the 
incidence of a condition in a given population is high. Accordingly, it is well 
known that patients treated with oral bisphosphonates have a good response in 
turnover markers. Moreover, a screening test has to be easy to perform, widely 
available, cheap, common practice and needs to show a high sensitivity 
(detection rate). In other words, the detection rate for the decrease of BTMs 
(beyond the LSC) should be very high to minimize the proportion of false 
negative tests. Therefore, the present recommendations are in accordance with 
all these principles and can be translated to clinical practice. 
  We use the statistic ‘detection rate’. Detection rate has been considered as 
synonymous with sensitivity (14) although these concepts are not identical. For 
calculating sensitivity a gold standard test is needed and, from that, a 2x2 table 
can be built and sensitivity estimated. For the clinical assessment of the exposure 
of bone tissue to a drug, biochemical markers are the gold standard since 
obtaining bone biopsies is not acceptable and, moreover, in the largest series the 
correlation between markers and histomorphometry is moderately strong (15). 
Moreover, bone histomorphometry predicts fracture in children poorly (16) and 
biochemical and histomorphometric indexes correlate moderately well in adults 
treated with denosumab (17) or teriparatide (18).  
The objective of the TRIO study used here as the basis for our analysis 
was perfectly in accordance with the required information needed for 
developing the current recommendations.  The data comprises the three first-
line (and most prescribed) oral bisphosphonates used for treating osteoporosis, 
at their licensed doses. In another publication, Sebba et al. used the biochemical 
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marker changes as response indicators (19) from the FACT (Fosamax Actonel 
Comparison Trial) study. They defined a CTX response of 60% and a PINP 
response of 50% as significant although they didn't provide any evidence for 
these cut-offs. The response rate detected by CTX at 3 months was 70% for 
alendronate and 40% for risedronate whereas for PINP was 77 and 50%.  The 
lower responder rate in FACT is likely to be due to less use of calcium and 
vitamin D supplements in that study as well as the greater estimates of LSC. 
Indeed the required variation in the individual patient should exceed the 
least significant change value, and this is the basis for making the clinical 
judgment about low adherence or underlying causes of impaired response such 
as undiagnosed secondary osteoporosis or medications that interfere with the 
effect of the drug (20). The LSC thresholds of the TRIO study here used (11) are 
comparable with those previously reported in the literature as summarized in 
Table 4 (21-23). In the field of bone densitometry, it is regarded as good practice 
by the Internataion Society for Clinical Densitometry for each clinical centre to 
establish its own least significant change. This may be too onerous in practice to 
obtain for bone turnover markers.  
The results of the TRIO study also offer strength to the clinical 
recommendations because they represent the benchmark of what can be 
achieved in clinical practice from a controlled trial where the monitoring and 
adherence are the best that can be obtained. The timing for assessment, three 
months after prescription (decision to treat) and in most cases acceptance (start 
of the therapy), is optimal because the changes in the markers are already 
complete although the same performance of the screening can be expected if for 
some reason the second measurement is made later on, at six or even 12 months. 
The three month measurement is early enough to assess how the patient accepts 
and tolerates the treatment and also covers the critical period of primary non-
adherence, in the first weeks after the prescription is given when patients may 
have discontinued treatment or may never have started (12). Some limitations 
should be also mentioned. The results of the TRIO study refer to postmenopausal 
women in a given geographical area and, therefore, their translation to men and 
premenopausal patients as well as to other areas has to be extrapolated. 
Furthermore, the small number of participants  is another limitation although 
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TRIO is a study that specifically addresses our research question. We found no 
systematic study on men and young women and so we could speculate that they 
would have the same response rate. However, more research on this aspect is 
needed and further validation of the results obtained in  the TRIO study in 
different clinical trials and/or different drugs must be obtained to fully certify 
the proposed strategy. 
Moreover, the results in real world practice are always expected to be 
worse, in terms of adherence, than what is observed in a clinical trial. However, 
this is why the TRIO results should be considered as a benchmark of the best 
possible scenario under ideal conditions of practice. The cost of the test, in 
settings where are not covered by reimbursement policies, may be another 
practical limitation. Finally, the biological variability of CTX is quite large when it 
is evaluated in a sufficiently large population. 
There is an alternative way to evaluating treatment response that was 
described for the TRIO study. Sometimes we don't have a baseline BTMs result. It 
would appear that most patients before treatment are above the average value 
for young women and most women on treatment are below this value. Thus, a 
second approach to identifying response could be to measure BTMs on 
treatment and if the value is below the young normal mean (e.g. PINP 35 ug/L, 
CTX 25 ng/L) then consider that adequate suppression of bone turnover that 
wouldn't happen if treatment was not taken. However, we believe that not 
having baseline determinations of bone markers adds uncertainty and makes 
hard to apply this screening strategy. 
Can other commonly used assays for CTX and PINP (such as the assays 
offered by Roche Diagnostics) be used in the samem way as the IDS assays used 
in TRIO? We don’t know of any side by side comparison of serum CTX and PINP 
by the IDS and other assays for treatment response. However, the antibody used 
by the two suppliers of CTX assays are the same, so it is likely that the percentage 
response and probably the LSC will be similar. The PINP assays from IDS and 
Roche do differ in that the IDS measures only intact PINP whereas Roche 
measures both the intact and the monomer forms. However, this doesn’t seem to 
affect the absolute value of the PINP and only seems to be a problem in end-stage 
renal disease. 
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The working group does not suggest that this screening strategy will have 
a direct impact on adherence. It may be interesting to further evaluate whether 
these recommendations have an impact on medication adherence in a real-life 
setting, considering also the cost-effectiveness balance.  Adherence is a complex 
issue and interventions address the specific perceptions (e.g. patient’s beliefs 
about osteoporosis and its treatment) and practicalities (e.g. capability and 
resources) influencing the motivation and ability to start and continue with the 
treatment. (24) However, assessing adherence is a crucial first step to any 
intervention and the feedback to the patient has to ensure a no-blame approach 
and be made in the context of their behavior and beliefs characteristics. 
Bone densitometry is the most commonly used method for measuring the 
effect of treatments in clinical practice and its value for defining the goal of 
therapies is currently one of the hot topics in the field. However the time 
required for detecting a significant variation is considerably longer than for 
biochemical markers. This fact limits the clinical utility of BMD monitoring for an 
early assessment of the effect of oral bisphosphonates, precisely when most of 
the adherence problems occur. 
In summary, the Working Group proposes measurement of PINP and CTX 
levels at baseline and after three months of initiating treatment. In those 
individuals where the decrease does not exceed the least significant change (38 
and 56%, respectively) assessment of adherence or, eventually, investigation of 
secondary osteoporosis  (9), should be carried out. 
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Figure legends 
 
Figure 1 
1 Change from baseline after three months of treatment with the three tested 
bisphosphonates (Ibandronate, Alendronate and Risedronate) in CTX (upper 
panel) and PINP (lower panel). Shadowed zone indicates change > least 
significant change for the marker  
 
Figure 2 
Algorithm for the assessment of adherence based on the measurement of CTX 
and/or PINP 
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Table 1. Values of biochemical markers at baseline and after three months of 
treatment and percentage of decrease for each of the treatment groups 
   
Ibandronate Alendronate Risedronate Young 
controls 
N 57 57 58 87 
CTX, ng/mL, 
mean baseline 
0.68 0.64 0.59 0.32 
CTX response,       
3 months, % 
decrease 
73 81 68 -- 
% of CTX 
responders,          
3 months*  
84 98 78 -- 
PINP, ng/mL, 
mean baseline 
49.9 46.2 44.0 29.0 
PINP response, 3 
months, % 
decrease 
63 56 48 -- 
% of PINP 
responders,           
3 months*  
94 82 75 -- 
  
* % of patients with a decrease at three months > least significant change (LSC). 
LSC based on CTX values was defined as a decrease of 56%, based on PINP by 
38% 
Thus, with serum CTX 78-98% of women, and with serum PINP 75-94% of 
women are considered 'responders' after 3 months of treatment, depending on 
the bisphosphonate used.  
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Table 2. Relationship between adherence* and response to daily treatment with 
oral risedronate (25) 
 
Tablets taken Mean % change Responders, % 
<26 -36 56 
26-52 -42 59 
52-78 -49 72 
78-104 -62 64 
>104 -63 87 
 
* Adherence measured at 48 weeks. Responders are considered the individual 
patients that show changes in BTMs that exceed the LSC.   
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Table 3. Detection rate as percent of cases in the overall cohort with the 
prespecified decrease>LSC in CTX, PINP or both after the initiation of treatment 
 
 
BTM N N with 
decrease>LSC 
N  with 
decrease 
<LSC 
Detection 
rate (%) 
     
CTX 146 127 19 86.9 
PINP 149 125 24 83.9 
CTX+PINP 146 138 8 94.5 
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Table 4. LSC thresholds of the TRIO study compared with those previously 
reported  
  
BTM LSC %       
  Naylor            
OI 2015 
 (11) 
Fink            
OI 2000 
(26) 
Hannon            
JBMR 1998 
 (22) 
Rogers          
Bone 2009 
 (23) 
CTX 56 57 67 28 
PINP 38 38 40 25 
  
 
The methods used were: Naylor automated (IDS), Fink, Hannon and Rogers 
manual assays.  
The only estimate of the LSC we have found was for CTX of 27% (27) (Garnero 
2001) and PINP of 20% (28) (Garnero 2008) on the Roche Elecsys. 
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Figure 1  
 
 Ibn= Ibandronate; Aln = Alendronate; Ris = Risedronate 
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Figure 2.  
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